Ruifang Niu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ruifang Niu has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Fei Zhang
Public Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China
24 shared publications - Weijie Song
Laboratory Animal Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China
20 shared publications - Ben Liu
Department of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, Ministry of Education, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China
17 shared publications - Cong Xia
Department of Public Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China
17 shared publications - Fangdi Zou
Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China
17 shared publications - Haixin Li
Tianjin Tissue Bank, Key Laboratory of Cancer Prevention and Therapy, Tianjin Key Laboratory of Digestive Cancer, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Prevention and Control of Major Diseases in the Population, Tianjin Medical University Cancer Institute and Hospital, Ministry of Education, Tianjin Medical University, Tianjin, China
17 shared publications
Latest Publications
- Open Access
- 29 August 2026
- Published by Springer Nature in Cancer Cell International
Immune infiltration-based prognostic signature for molecular subtyping and therapeutic stratification in lung adenocarcinoma
- 29 August 2026
- Published by Springer Nature in Cancer Cell International
Open AccessImmune infiltration-based prognostic signature for molecular subtyping and therapeutic stratification in lung adenocarcinoma
- Open Access
- 23 February 2026
- Published by China Anti-cancer Association in Cancer Biology & Medicine
- p. 1-28
Exosomal EPHA2 transfers metastatic potential by stabilizing TGF-βRI and activating the TGF-β/SMAD3 signaling pathway in breast cancer
Objective: Intratumoral heterogeneity refers to the presence of distinct subpopulations of cancer cells within a single tumor, which exhibits variations in phenotypic traits, such as proliferation rate, drug sensitivity, and metastatic potential. Dynamic interactions among heterogeneous cell populations have a critical role in tumor progression. Increasing evidence underscores the importance of intercellular communication among heterogeneous cancer cell subpopulations in driving malignancy. However, the molecular mechanisms governing such cancer cell-to-cancer cell interactions are poorly understood. Methods: Exosomes were isolated from highly metastatic breast cancer cells (HM-BCCs) and low metastatic breast cancer cells (LM-BCCs). The role of exosome-mediated intercellular communication on metastatic behavior was assessed using wound healing and Transwell assays. Gene knockdown and overexpression strategies, small-molecule inhibitors, and xenograft mouse models were used to elucidate the role of exosomal EPHA2. Results: Exosomes derived from HM-BCCs considerably enhanced the migratory and invasive capabilities of LM-BCCs in vitro and increased the metastatic potential in vivo. Mechanistically, EPHA2 was identified as a key protein enriched in exosomes from HM-BCCs and was shown to be transferred to LM-BCCs by these vesicles. Exosomal EPHA2 promoted epithelial-to-mesenchymal transition in LM-BCCs when internalized by stabilizing TGF-βRI and activating the transforming growth factor-β/mothers against decapentaplegic homolog 3 (TGF-β/SMAD3) signaling pathway, thereby facilitating the acquisition of a metastatic phenotype. Conclusions: The results underscore the pivotal function of exosomal EPHA2 in mediating the transfer of metastatic potential among heterogeneous breast cancer cell populations. Targeting the EPHA2-TGF-βRI signaling axis may provide a novel therapeutic approach for preventing or limiting breast cancer metastasis.
- 23 February 2026
- Published by China Anti-cancer Association in Cancer Biology & Medicine
- p. 1-28
Open AccessExosomal EPHA2 transfers metastatic potential by stabilizing TGF-βRI and activating the TGF-β/SMAD3 signaling pathway in breast cancer
Objective: Intratumoral heterogeneity refers to the presence of distinct subpopulations of cancer cells within a single tumor, which exhibits variations in phenotypic traits, such as proliferation rate, drug sensitivity, and metastatic potential. Dynamic interactions among heterogeneous cell populations have a critical role in tumor progression. Increasing evidence underscores the importance of intercellular communication among heterogeneous cancer cell subpopulations in driving malignancy. However, the molecular mechanisms governing such cancer cell-to-cancer cell interactions are poorly understood. Methods: Exosomes were isolated from highly metastatic breast cancer cells (HM-BCCs) and low metastatic breast cancer cells (LM-BCCs). The role of exosome-mediated intercellular communication on metastatic behavior was assessed using wound healing and Transwell assays. Gene knockdown and overexpression strategies, small-molecule inhibitors, and xenograft mouse models were used to elucidate the role of exosomal EPHA2. Results: Exosomes derived from HM-BCCs considerably enhanced the migratory and invasive capabilities of LM-BCCs in vitro and increased the metastatic potential in vivo. Mechanistically, EPHA2 was identified as a key protein enriched in exosomes from HM-BCCs and was shown to be transferred to LM-BCCs by these vesicles. Exosomal EPHA2 promoted epithelial-to-mesenchymal transition in LM-BCCs when internalized by stabilizing TGF-βRI and activating the transforming growth factor-β/mothers against decapentaplegic homolog 3 (TGF-β/SMAD3) signaling pathway, thereby facilitating the acquisition of a metastatic phenotype. Conclusions: The results underscore the pivotal function of exosomal EPHA2 in mediating the transfer of metastatic potential among heterogeneous breast cancer cell populations. Targeting the EPHA2-TGF-βRI signaling axis may provide a novel therapeutic approach for preventing or limiting breast cancer metastasis.
Fructose drives colorectal cancer progression by regulating crosstalk between cancer-associated fibroblasts and tumour cells
Background Fructose has been identified as a potential alternative energy source for cancer cells, facilitated by the fructose-specific transporter GLUT5. Elevated GLUT5 expression in cancer cells has been associated with increased tumour aggressiveness. However, the role of fructose in remodelling the tumour microenvironment, particularly in modulating cancer-associated fibroblast (CAF) behaviour, remains underexplored. Objective This study aimed to elucidate the regulatory effects and molecular mechanisms of fructose-mediated CAF reprogramming in colorectal cancer (CRC) progression. Design The effects of fructose and fructose-cultured tumour cells on biological function of CAFs were detected. Metabolomics and transcriptomic analyses were used to characterise the fructose-regulated crosstalk network of tumour cells and CAFs. Furthermore, the relationships between GLUT5 expression level in CAFs and clinicopathological features and prognosis of patients with CRC were analysed. Results We demonstrate that fructose plays a dual role in promoting CRC progression by influencing both tumour cells and CAFs. GLUT5 is expressed in both CRC cells and CAFs, with its expression correlating with more advanced tumour stages and poorer outcomes in patients. Fructose metabolism in CAFs enhances their proliferation, migration and activation, while fructose utilisation by CRC cells leads to the release of nucleotides and amino acids. These metabolites activate CAFs and upregulate the expression of the chemokine CXCL14. This, in turn, promotes tumour cell migration and metastasis. Conclusions These findings reveal a novel mechanism by which fructose fosters tumour progression through the modulation of tumour-stroma interactions, and highlight the therapeutic potential of targeting fructose metabolism in CRC to disrupt the tumour-stroma crosstalk that drives malignancy.
Fructose drives colorectal cancer progression by regulating crosstalk between cancer-associated fibroblasts and tumour cells
Background Fructose has been identified as a potential alternative energy source for cancer cells, facilitated by the fructose-specific transporter GLUT5. Elevated GLUT5 expression in cancer cells has been associated with increased tumour aggressiveness. However, the role of fructose in remodelling the tumour microenvironment, particularly in modulating cancer-associated fibroblast (CAF) behaviour, remains underexplored. Objective This study aimed to elucidate the regulatory effects and molecular mechanisms of fructose-mediated CAF reprogramming in colorectal cancer (CRC) progression. Design The effects of fructose and fructose-cultured tumour cells on biological function of CAFs were detected. Metabolomics and transcriptomic analyses were used to characterise the fructose-regulated crosstalk network of tumour cells and CAFs. Furthermore, the relationships between GLUT5 expression level in CAFs and clinicopathological features and prognosis of patients with CRC were analysed. Results We demonstrate that fructose plays a dual role in promoting CRC progression by influencing both tumour cells and CAFs. GLUT5 is expressed in both CRC cells and CAFs, with its expression correlating with more advanced tumour stages and poorer outcomes in patients. Fructose metabolism in CAFs enhances their proliferation, migration and activation, while fructose utilisation by CRC cells leads to the release of nucleotides and amino acids. These metabolites activate CAFs and upregulate the expression of the chemokine CXCL14. This, in turn, promotes tumour cell migration and metastasis. Conclusions These findings reveal a novel mechanism by which fructose fosters tumour progression through the modulation of tumour-stroma interactions, and highlight the therapeutic potential of targeting fructose metabolism in CRC to disrupt the tumour-stroma crosstalk that drives malignancy.
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S14 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
Schematic of AAV8.sgCRTC2 gene therapy in HCC mouse model.
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S14 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
Schematic of AAV8.sgCRTC2 gene therapy in HCC mouse model.
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S10 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
Identification of CRTC2–YTHDF2 co-condensate m6A-RNAs.
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
Identification of CRTC2–YTHDF2 co-condensate m6A-RNAs.
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
The location and function of TurboID-tagged CRTC2 are similar to wild-type CRTC2.
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
The location and function of TurboID-tagged CRTC2 are similar to wild-type CRTC2.
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S9 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
CRTC2 promotes HCC progression dependent on YTHDF2.
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
CRTC2 promotes HCC progression dependent on YTHDF2.
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
CRTC2 condensates promote HCC initiation and progression in vivo and in vitro.
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
CRTC2 condensates promote HCC initiation and progression in vivo and in vitro.
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
Knockout of CRTC2 impairs proliferation of HCC cells.
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
Knockout of CRTC2 impairs proliferation of HCC cells.
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S12 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
Schematic of AAV8.sgCRTC2 gene therapy in DEN/CCl4-HCC model.
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
Schematic of AAV8.sgCRTC2 gene therapy in DEN/CCl4-HCC model.